RESUMO
Objective To analyse the effect of recombinant endostatin on Treg, CD8 +T cells, tumor specific growth factor (TSGF) in peripheral blood of patients with advanced esophageal gastric junction adenocarcinoma and clinical efficacy observation.Methods 52 patients who were diagnosed with acute cerebral infarction in our hospital were collected.All patients were randomly divided into experimental group and control group, 26 cases in each group.The control group was given OLF chemotherapy, the experimental group was treated with OLF chemotherapy regimen combined with recombinant endostatin.21 days was 1 cycle, a total of 4 cycles.After treatment, the levels of Treg, CD8 +T cells, serum TSGF and clinical efficacy were detected in all patients.ResuIts After treatment, compared with control group,the peripheral blood Treg was significantly lower in the experimental group (P<0.05); the peripheral blood CD8 +T cells level in the experimental group was significantly higher (P<0.05);the serum TSGF level in the experimental group was significantly lower ( P<0.05 ); the effective of patients in the experimental group was higher ( P<0.05 ) . ConcIusion Recombinant endostatin can significantly reduce the levels of Treg and serum TSGF in patients with advanced esophageal gastric junction adenocarcinoma, improve the level of CD8 +T cells, and improve the efficiency of treatment, have guiding significance to clinical.